Current status of immunotherapy for advanced gastric cancer.

Abstract

Recently, immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) or programmed cell death ligand-1 (PD-L1) monoclonal antibodies have improved the overall survival of various types of cancers including advanced gastric cancer (AGC). Until now, two ant-PD-1 inhibitors were approved for AGC in Japan: nivolumab as third- or later-line treatment for AGC and pembrolizumab for previously treated patients with microsatellite instability-high tumours. However, a limited number of patients achieved clinical benefit, highlighting the importance of the better selection of patients or additional treatment to overcome resistance to PD-1/PD-L1 blockade. This review focused on pivotal clinical trials, biomarkers and novel combination therapy of immune checkpoint inhibitors forAGC.

• Authors: Akihito Kawazoe, Kohei Shitara, Narikazu Boku, Takaki Yoshikawa, Masanori Terashima
• Journal: Japanese journal of clinical oncology (Jpn J Clin Oncol) Vol. 51 Issue 1 Pg. 20-27 (Jan 01 2021) ISSN: 1465-3621 [Electronic] England
• PMID: 33241322 (Publication Type: Journal Article, Review)
• Copyright: © The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: [email protected].

Chemical References

• Antibodies, Monoclonal, Humanized
• Immune Checkpoint Inhibitors
• Nivolumab
• pembrolizumab

Topics

• Antibodies, Monoclonal, Humanized (therapeutic use)
• Clinical Trials as Topic
• Combined Modality Therapy
• Humans
• Immune Checkpoint Inhibitors (therapeutic use)
• Immunotherapy
• Microsatellite Instability
• Nivolumab (therapeutic use)
• Stomach Neoplasms (drug therapy, genetics)